AVIRAtea Pharmaceuticals, Inc.

Nasdaq ateapharma.com


$ 3.89 $ -0.04 (-1.02 %)    

Friday, 10-May-2024 15:59:55 EDT
QQQ $ 441.71 $ 1.04 (0.24 %)
DIA $ 395.04 $ 1.18 (0.3 %)
SPY $ 520.76 $ 0.67 (0.13 %)
TLT $ 90.14 $ -0.51 (-0.56 %)
GLD $ 218.73 $ 1.76 (0.81 %)
$ 3.89
$ 3.97
$ 0.00 x 0
$ 0.00 x 0
$ 3.88 - $ 3.97
$ 2.77 - $ 5.19
155,489
na
324.39M
$ 0.70
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-28-2024 12-31-2023 10-K
2 11-08-2023 09-30-2023 10-Q
3 08-08-2023 06-30-2023 10-Q
4 05-08-2023 03-31-2023 10-Q
5 02-28-2023 12-31-2022 10-K
6 11-07-2022 09-30-2022 10-Q
7 08-08-2022 06-30-2022 10-Q
8 05-10-2022 03-31-2022 10-Q
9 02-28-2022 12-31-2021 10-K
10 11-12-2021 09-30-2021 10-Q
11 08-12-2021 06-30-2021 10-Q
12 05-13-2021 03-31-2021 10-Q
13 03-30-2021 12-31-2020 10-K
14 12-10-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 atea-pharmaceuticals-q4-2023-gaap-eps-047-beats-051-estimate

Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of ...

 earnings-scheduled-for-february-28-2024

Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenu...

 atea-pharmaceuticals-hepatitis-c-virus-candidate-shows-efficacy

Atea Pharmaceuticals Inc (NASDAQ: AVIR) reported initial data from the first 52 patients in the lead-in cohort of its Phase 2 c...

 atea-pharmaceuticals-announces-initial-data-from-phase-2-study-for-hepatitis-c-virus-and-significant-enrollment-milestone-for-phase-3-sunrise-3-trial-for-covid-19

A 98% Sustained Virologic Response at Week 4 (SVR4) Post-Treatment Observed in Initial Data From 52 Patients in Lead-In Cohort ...

 atea-pharmaceuticals-inc-receives-orphan-designation-status-from-us-fda-for-a-phosphoramidate-oral-prodrug-of-a-unique-6-modified-purine-nucleotide-for-treatment-of-disease-caused-by-dengue-virus

https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=976523  

 atea-pharmaceuticals-q3-eps-040-beats-048-estimate

Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of ...

 earnings-scheduled-for-november-8-2023

Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its third quarter.

 stocks-that-hit-52-week-lows-on-monday

  On Monday, 369 companies set new 52-week lows.

 jp-morgan-downgrades-atea-pharmaceuticals-to-underweight

JP Morgan analyst Eric Joseph downgrades Atea Pharmaceuticals (NASDAQ:AVIR) from Neutral to Underweight.

 atea-pharmaceuticals-q2-eps-034-beats-047-estimate

Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of ...

 earnings-scheduled-for-august-8-2023

Companies Reporting Before The Bell • Warner Music Gr (NASDAQ:WMG) is likely to report quarterly earnings at $0.21 per share o...

 atea-pharma-dosed-first-patient-in-phase-2-study-for-treatment-of-hepatitis-c-with-bemnifosbuvir-and-ruzasvir-combination

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery ...

 why-nvidia-shares-are-trading-higher-by-over-5-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Gainers QualTek Services Inc. (NASDAQ: QTEK) shares jumped 127.2% to $0.1740 after dropping around 21% on Friday. Qualtek S...

 skyline-champion-atea-pharmaceuticals-and-other-big-stocks-moving-lower-on-tuesday

U.S. stocks traded mixed, with the Dow Jones dropping over 100 points on Tuesday. Here are some big stocks recording losses in ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION